Navigation Links
Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Date:1/12/2009

Primary Businesses

-- Cataract Surgery/IOL: Devices for cataract surgery, which replaces a patient's aging and cloudy natural lens with an IOL or artificial lens to restore vision.

-- Laser Vision Correction (LASIK): Devices used for refractive laser eye surgery to correct myopia (nearsightedness), hyper-opia (farsightedness) and astigmatism (condition that causes blurred vision).

-- Eye Care: Contact lens care products including multi-purpose cleaning and disinfecting solutions, daily cleaners and contact lens rewetting drops; and over-the-counter dry eye products.

Products

-- Cataract Surgery/IOL: WhiteStar Signature(TM) Phacoemulsification System, Healon(R) Viscoelastics, Tecnis(R) Aspheric IOL, Tecnis(R) Multifocal IOL, ReZoom(R) Multifocal IOL, Verisyse(R) Phakic IOL.

-- Laser Vision Correction (LASIK): iLASIK(TM), VISX(TM) Excimer Technology, IntraLase(TM) FS Technology, Advanced CustomVue(TM) Procedure.

-- Eye Care: COMPLETE(R) Multi-Purpose Solution, Blink Contacts(TM) Lubricant Eye Drops, Oxysept(R) UltraCare Formula, Blink(R) Tears Lubricating Eye Drops

Vision Facts

-- About 60 percent of people 60+ years old have cataracts.

-- The global population is aging at unprecedented levels. There are more than 700 million people globally older than 60 (up from 600 million in 2000); by 2020, this number is projected to increase to 1 billion.

-- Cataracts are the leading cause of vision loss among people 55 and older.

-- More than 15 million cataract procedures are performed worldwide annually.

-- Approximately 52 percent of people have some form of myopia or hyperopia.

More than 3.5 million LASIK procedures are performed globally annually; LASIK accounts for more than 90 percent of all U.S. refractive surgical procedures.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Abbott Announces Earnings Guidance for 2009
2. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
3. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
4. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott to Present at UBS Best of Americas Investment Conference
7. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
8. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
9. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... BALTIMORE, March 24, 2011 Champions Biotechnology, Inc. ... a technology collaboration agreement with Cephalon, Inc. in ... on two proprietary chemical compounds, CEP-32496, an inhibitor ... ALK-FAK inhibitor, provided by Cephalon to determine the ...
... Calif., March 24, 2011 ValGenesis, Inc., an ... solutions, today announced the availability of its industry-proven ... (SaaS) offering hosted on MUSA,s Validated Cloud. ... Lifecycle Management solution accessible via the Internet through ...
... Rules-Based Medicine, Inc. (RBM), a leading provider of innovative ... OncologyMAP ® , a powerful tool developed at the ... Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP ... on biological pathways that could hold the key to ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development 2
(Date:4/17/2014)... inhibits RSV infection , Respiratory syncytial virus ... tract infections, generating life-threating illness in very young ... are limited. RSV enters host cells through the ... fusogenic bundle. Small interfering peptides that prevent bundle ... peptides are highly susceptible to degradation. In this ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... 16, 2011The American Association for the Advancement of ... Srivastava, MD, a Fellow for his efforts to ... directs cardiac and stem cell research at Gladstone, ... research efforts are focused in the areas of ...
... (OGI) has awarded two research facilities with $10,000 each ... the work of Ontario researchers., ,The two recipients ... The Hospital for Sick Children (SickKids) in Toronto and ... StemCore Laboratories based at the Ottawa Hospital Research Institute. ...
... animal, from a blue whale to a human being, ... the cells in its body will die without reproducing; ... the next generation. How could the extreme degree ... aren,t all creatures unicellular individualists determined to pass on ...
Cached Biology News:Gladstone scientist Deepak Srivastava named fellow of the AAAS 22 research facilities awarded technology seeding grants 2Close family ties keep microbial cheaters in check, study finds 2Close family ties keep microbial cheaters in check, study finds 3Close family ties keep microbial cheaters in check, study finds 4Close family ties keep microbial cheaters in check, study finds 5
... protein assay kit I provides reagents and a ... presence of reducing agents and detergents. The RC ... kit includes reagents and standards sufficient for 500 ... ml RC reagent II, 250 ml alkaline copper ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... three-color reagent kit for determining the absolute ... blood samples, mobilized peripheral blood samples, and ... a total nucleated cell count and a ... is designed for use in the BD ...
... Rhodopsin is a glycoprotein which is ... and reptiles. The rhodopsin protein is present ... Immunogen: Membrane preparation from ... This antibody specifically labels the axons andsynaptic ...
Biology Products: